{
    "clinical_study": {
        "@rank": "4776", 
        "arm_group": [
            {
                "arm_group_label": "PhtD Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive PhtD vaccine formulation 1 without any adjuvant."
            }, 
            {
                "arm_group_label": "PhtD Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive adjuvanted PhtD vaccine formulation 2."
            }, 
            {
                "arm_group_label": "PhtD Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive adjuvanted PhtD vaccine formulation 3."
            }, 
            {
                "arm_group_label": "PhtD Group 4", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive adjuvanted PhtD vaccine formulation 4."
            }, 
            {
                "arm_group_label": "PhtD Group 5", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive adjuvanted PhtD vaccine formulation 5."
            }, 
            {
                "arm_group_label": "23 PPV Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive the Pneumovax 23TM vaccine and NaCl."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the safety, reactogenicity and immunogenicity of the\n      GlaxoSmithKline (GSK) Biologicals candidate pneumococcal vaccine containing PhtD in healthy\n      elderly population aged 18-45 years of age."
        }, 
        "brief_title": "Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults", 
        "completion_date": {
            "#text": "November 2004", 
            "@type": "Actual"
        }, 
        "condition": "Pneumococcal Disease", 
        "detailed_description": {
            "textblock": "The safety profile of the PhtD vaccine will be assessed in comparison to a comparator\n      vaccine (Pneumovax 23TM). In order to further increase the immune response to vaccination, a\n      novel adjuvant system will also be examined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes will comply with the requirements of the\n             protocol should be enrolled in the study.\n\n          -  A male or female between, and including, 18 and 45 years at the time of the first\n             vaccination.\n\n          -  Written informed consent obtained from the subject.\n\n          -  Free of obvious health problems as established by medical history and clinical\n             examination before entering into the study.\n\n          -  If the subject is female, she must be of non-childbearing potential, i.e., either\n             surgically sterilized or one year post-menopausal; or, if of childbearing potential,\n             she must be abstinent or have used adequate contraceptive precautions for 30 days\n             prior to vaccination, have a negative pregnancy test and must agree to continue such\n             precautions for two months after completion of the vaccination series.\n\n        Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product other than the study vaccine(s)\n             within 30 days preceding the first dose of study vaccine, or planned use during the\n             study period or participation to another pharmaceutical/vaccine study.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs within\n             six months prior to the first vaccine dose.\n\n          -  Use of any anticoagulants.\n\n          -  Planned administration/ administration of a vaccine not foreseen by the study\n             protocol within 2 weeks of the first dose of vaccines.\n\n          -  Previous vaccination against Streptococcus pneumoniae.\n\n          -  Bacterial pneumonia within 3 years prior to 1st vaccination.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including\n             human immunodeficiency virus (HIV) infection.\n\n          -  History of allergic disease or reactions likely to be exacerbated by any component of\n             the vaccine.\n\n          -  Current serious neurologic or mental disorders.\n\n          -  Inflammatory processes such as known chronic active infections.\n\n          -  All malignancies (excluding non-melanic skin cancer) and lymphoproliferative\n             disorders diagnosed or treated actively during the past 5 years.\n\n          -  History of administration of an experimental vaccine containing 3-deacylated\n             Monophosphoryl Lipid A (MPL) or Quillaja saponaria 21 (QS21).\n\n          -  Acute disease at the time of enrolment. All vaccines can be administered to persons\n             with a minor illness such as diarrhea, mild upper respiratory infection with or\n             without low-grade febrile illness, i.e., Oral temperature <37.5\u00b0C or Axillary\n             temperature <37.5\u00b0C.\n\n          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal\n             functional abnormality, as determined by physical examination or laboratory screening\n             tests, at the discretion of the investigator.\n\n          -  Pregnant or lactating female.\n\n          -  History of chronic alcohol consumption and/or intravenous drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767402", 
            "org_study_id": "100417"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PhtD Group 5", 
                    "PhtD Group 2", 
                    "PhtD Group 4", 
                    "PhtD Group 1", 
                    "PhtD Group 3"
                ], 
                "description": "Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.", 
                "intervention_name": "PhtD vaccine with/without adjuvant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "23 PPV Group", 
                "description": "One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.", 
                "intervention_name": "Pneumovax 23TM", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "23 PPV Group", 
                "description": "One dose administered intramuscularly in  the deltoid region of the right arm at month 2.", 
                "intervention_name": "NaCl", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "Pneumococcal Infections", 
            "Immunogenicity", 
            "PhtD vaccine", 
            "Healthy adults", 
            "Reactogenicity"
        ], 
        "lastchanged_date": "January 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bruxelles", 
                    "country": "Belgium", 
                    "zip": "1200"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations According to a 0-2 Month Schedule, in Healthy Adults", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Occurrence, intensity and relationship of any solicited local and general signs and symptoms", 
                "safety_issue": "No", 
                "time_frame": "During a 7-day follow up period (i.e. Days 0-6) after each vaccine dose"
            }, 
            {
                "measure": "Occurrence, intensity and relationship to vaccination of unsolicited local and general signs and symptoms", 
                "safety_issue": "No", 
                "time_frame": "During a 30-day follow up period (i.e. Days 0-29) after each vaccine dose"
            }, 
            {
                "measure": "Occurrence of all serious adverse events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "During the 12 months of the study"
            }, 
            {
                "measure": "Anti-PhtD antibody concentration in all vaccine groups (measured by ELISA)", 
                "safety_issue": "No", 
                "time_frame": "One month after the first injection"
            }, 
            {
                "measure": "Anti-PhtD antibody concentration in all vaccine groups (measured by ELISA)", 
                "safety_issue": "No", 
                "time_frame": "One month after two injections"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767402"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number and percentage of subjects with normal or abnormal values, for biochemical assessments and for hematological analysis", 
                "safety_issue": "No", 
                "time_frame": "At month 0, 1, 3 and 12"
            }, 
            {
                "measure": "Anti-PhtD antibody concentration in all groups (measured by ELISA)", 
                "safety_issue": "No", 
                "time_frame": "At 12 months after the first vaccination"
            }, 
            {
                "measure": "Anti-PhtD antibody avidity (measured by ELISA)", 
                "safety_issue": "No", 
                "time_frame": "At month 0, 1, 3 and 12"
            }, 
            {
                "measure": "Evaluation of protection afforded by passive transfer of anti PhtD antibodies sera pooled from all individuals (passive transfer mice model assay)", 
                "safety_issue": "No", 
                "time_frame": "At month 0, 1, 3 and 12"
            }, 
            {
                "measure": "Frequency of PhtD-specific plasma cells generated by in vitro cultivated memory B-cells in a subset of subjects (measured by B-cell ELISPOT)", 
                "safety_issue": "No", 
                "time_frame": "At month 0, 3 and 12"
            }, 
            {
                "measure": "Frequency of CD4 and/or CD8 T cells that produce cytokines IL-2, IL-4, IFNg, CD40L and/or GM-CSF, upon PhtD re-stimulation in vitro, to evaluate the T-cell response, in a subset of subjects (measured by intracellular cytokine cytometry)", 
                "safety_issue": "No", 
                "time_frame": "At month 0, 3 and 12"
            }, 
            {
                "measure": "Anti-polysaccharide total gamma class immunoglobulin (IgG) concentration in the 23 valent Polysaccharide Pneumococcal Vaccine(23 PPV) group for 11 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) (ELISA)", 
                "safety_issue": "No", 
                "time_frame": "At month 0, 1 and 12"
            }, 
            {
                "measure": "Opsonophagocytic activity titers in the 23 PPV group for 11 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F (OPA assay)", 
                "safety_issue": "No", 
                "time_frame": "At month 0, 1 and 12"
            }, 
            {
                "measure": "Frequency of polysaccharide(PS)-specific plasma cells generated by in vitro cultivated memory B-cells in the 23 PPV group in a subset of subjects (measured by B-cell ELISPOT)", 
                "safety_issue": "No", 
                "time_frame": "At month 0, 1 and 12"
            }, 
            {
                "measure": "Circulating serum cytokines Interferon-gamma (INF\u03b3) and Tumor necrosis factor-alpha (TNF\u03b1) content in all groups (measured by ELISA)", 
                "safety_issue": "No", 
                "time_frame": "At Day 0, 1, 60 and 61"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2003", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}